(SECARE) Swedencare publ - Ratings and Ratios
Supplements, Treats, Grooming, Dental, Pharmaceuticals
SECARE EPS (Earnings per Share)
SECARE Revenue
Description: SECARE Swedencare publ
Swedencare AB (publ) is a leading animal healthcare company that develops, manufactures, and markets a diverse range of products for cats, dogs, and horses across North America, Europe, and internationally. The companys product portfolio includes nutritional supplements, treats, grooming products, and pharmaceutical-grade health products under various brand names, such as Healthy Breeds, Innovet, and Stratford Animal Health.
The companys strong brand presence is reflected in its diverse product offerings, which cater to various therapeutic areas, including orthopedics, behavior, dermatology, and gastroenterology. Swedencares products are distributed through veterinarians, pet stores, and online channels, providing a robust distribution network. Key Performance Indicators (KPIs) to watch include revenue growth, gross margin expansion, and operating profit margin improvement.
From a financial perspective, Swedencares market capitalization stands at approximately 7.49 billion SEK, indicating a significant market presence. The companys price-to-earnings (P/E) ratio is 81.29, suggesting a relatively high valuation. However, the forward P/E ratio is 36.36, indicating potential for earnings growth. Return on Equity (RoE) is currently at 1.22%, which is a relatively low figure, but this may be an area for improvement as the company continues to grow and expand its product offerings.
To further evaluate Swedencares performance, other relevant KPIs could include sales growth rate, customer acquisition costs, and product development pipeline. Additionally, investors may want to monitor the companys ability to expand its distribution channels, enhance its product portfolio, and improve its operational efficiency. By analyzing these KPIs, stakeholders can gain a more comprehensive understanding of Swedencares financial and operational performance.
SECARE Stock Overview
| Market Cap in USD | 679m |
| Sub-Industry | Biotechnology |
| IPO / Inception |
SECARE Stock Ratings
| Growth Rating | -38.9% |
| Fundamental | 52.2% |
| Dividend Rating | 57.8% |
| Return 12m vs S&P 500 | -29.2% |
| Analyst Rating | - |
SECARE Dividends
| Dividend Yield 12m | 0.61% |
| Yield on Cost 5y | 0.81% |
| Annual Growth 5y | 10.44% |
| Payout Consistency | 100.0% |
| Payout Ratio | 38.3% |
SECARE Growth Ratios
| Growth Correlation 3m | -51.6% |
| Growth Correlation 12m | -48.9% |
| Growth Correlation 5y | -54.4% |
| CAGR 5y | -4.68% |
| CAGR/Max DD 3y | -0.09 |
| CAGR/Mean DD 3y | -0.18 |
| Sharpe Ratio 12m | -0.83 |
| Alpha | 0.00 |
| Beta | 0.995 |
| Volatility | 39.94% |
| Current Volume | 163.9k |
| Average Volume 20d | 250.9k |
| Stop Loss | 36.9 (-4.4%) |
| Signal | -0.72 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (64.8m TTM) > 0 and > 6% of Revenue (6% = 156.2m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -0.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 29.66% (prev 29.30%; Δ 0.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 336.8m > Net Income 64.8m (YES >=105%, WARN >=100%) |
| Net Debt (1.69b) to EBITDA (494.4m) ratio: 3.42 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (159.8m) change vs 12m ago 0.70% (target <= -2.0% for YES) |
| Gross Margin 57.31% (prev 31.82%; Δ 25.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 26.27% (prev 24.58%; Δ 1.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.50 (EBITDA TTM 494.4m / Interest Expense TTM 73.6m) >= 6 (WARN >= 3) |
Altman Z'' 0.97
| (A) 0.08 = (Total Current Assets 1.16b - Total Current Liabilities 388.6m) / Total Assets 9.78b |
| (B) 0.03 = Retained Earnings (Balance) 256.6m / Total Assets 9.78b |
| (C) 0.02 = EBIT TTM 183.9m / Avg Total Assets 9.91b |
| (D) 0.23 = Book Value of Equity 666.6m / Total Liabilities 2.85b |
| Total Rating: 0.97 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 52.23
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 3.72% = 1.86 |
| 3. FCF Margin 11.20% = 2.80 |
| 4. Debt/Equity 0.24 = 2.47 |
| 5. Debt/Ebitda 3.31 = -2.14 |
| 6. ROIC - WACC -6.51% = -8.14 |
| 7. RoE 0.88% = 0.07 |
| 8. Rev. Trend 90.41% = 6.78 |
| 9. EPS Trend 0.44% = 0.02 |
What is the price of SECARE shares?
Over the past week, the price has changed by -2.65%, over one month by +6.78%, over three months by -5.97% and over the past year by -15.90%.
Is Swedencare publ a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SECARE is around 34.44 SEK . This means that SECARE is currently overvalued and has a potential downside of -10.78%.
Is SECARE a buy, sell or hold?
What are the forecasts/targets for the SECARE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 49.7 | 28.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 38.2 | -1.1% |
SECARE Fundamental Data Overview
Market Cap SEK = 6.33b (6.33b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 124.0m SEK (last quarter)
P/E Trailing = 96.5854
P/E Forward = 25.9067
P/S = 2.4319
P/B = 0.9143
Beta = 0.773
Revenue TTM = 2.60b SEK
EBIT TTM = 183.9m SEK
EBITDA TTM = 494.4m SEK
Long Term Debt = 1.60b SEK (from longTermDebt, last quarter)
Short Term Debt = 40.1m SEK (from shortTermDebt, last quarter)
Debt = 1.64b SEK (Calculated: Short Term 40.1m + Long Term 1.60b)
Net Debt = 1.69b SEK (from netDebt column, last quarter)
Enterprise Value = 7.84b SEK (6.33b + Debt 1.64b - CCE 124.0m)
Interest Coverage Ratio = 2.50 (Ebit TTM 183.9m / Interest Expense TTM 73.6m)
FCF Yield = 3.72% (FCF TTM 291.6m / Enterprise Value 7.84b)
FCF Margin = 11.20% (FCF TTM 291.6m / Revenue TTM 2.60b)
Net Margin = 2.49% (Net Income TTM 64.8m / Revenue TTM 2.60b)
Gross Margin = 57.31% ((Revenue TTM 2.60b - Cost of Revenue TTM 1.11b) / Revenue TTM)
Tobins Q-Ratio = 11.76 (Enterprise Value 7.84b / Book Value Of Equity 666.6m)
Interest Expense / Debt = 1.16% (Interest Expense 18.9m / Debt 1.64b)
Taxrate = 34.29% (51.6m / 150.5m)
NOPAT = 120.8m (EBIT 183.9m * (1 - 34.29%))
Current Ratio = 2.99 (Total Current Assets 1.16b / Total Current Liabilities 388.6m)
Debt / Equity = 0.24 (Debt 1.64b / last Quarter total Stockholder Equity 6.92b)
Debt / EBITDA = 3.31 (Net Debt 1.69b / EBITDA 494.4m)
Debt / FCF = 5.61 (Debt 1.64b / FCF TTM 291.6m)
Total Stockholder Equity = 7.39b (last 4 quarters mean)
RoA = 0.66% (Net Income 64.8m, Total Assets 9.78b )
RoE = 0.88% (Net Income TTM 64.8m / Total Stockholder Equity 7.39b)
RoCE = 2.05% (Ebit 183.9m / (Equity 7.39b + L.T.Debt 1.60b))
RoIC = 1.34% (NOPAT 120.8m / Invested Capital 9.03b)
WACC = 7.85% (E(6.33b)/V(7.97b) * Re(9.68%)) + (D(1.64b)/V(7.97b) * Rd(1.16%) * (1-Tc(0.34)))
Shares Correlation 3-Years: 87.04 | Cagr: 0.10%
Discount Rate = 9.68% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.31% ; FCFE base≈315.4m ; Y1≈389.0m ; Y5≈663.8m
Fair Price DCF = 52.87 (DCF Value 8.45b / Shares Outstanding 159.8m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 0.44 | EPS CAGR: -13.71% | SUE: -1.11 | # QB: False
Revenue Correlation: 90.41 | Revenue CAGR: 11.28%